Key points are not available for this paper at this time.
From a Belgian payer perspective, PP with pegfilgrastim appears cost effective compared to other prophylaxis strategies in patients with stage II breast cancer or NHL at a €30,000/QALY threshold.
Lo et al. (Fri,) studied this question.